Tag
12 articles tagged markets.
Evonik's Q2 2026 adjusted EBITDA surged 24% to €630 million as crosslinkers, high-performance polymers, and amino acids defied macro headwinds - a signal worth parsing for the process analytics sector.
Shimadzu posted a sixth consecutive record quarter with Q1 FY2027 net sales of ¥130.6 billion, then raised its full-year guidance to ¥620 billion as the Tescan electron-microscope acquisition nears consolidation.
Roche's Diagnostics division posted CHF 6.7 billion in H1 2026, up 3% at constant exchange rates and 6% excluding China, where healthcare pricing reform continues to weigh on the segment.
Thermo Fisher reported Q2 2026 revenue of $11.99 billion, up 10%, with the Analytical Instruments segment growing 7% to $1.85 billion and adjusted operating margin lifting 420 basis points to 23.0%.
Air Liquide reported Q1 2026 sales of EUR 7,028 million on April 28, up 3.4 percent excluding currency and energy, with a record EUR 5.5 billion investment backlog and DIG Airgas closed in January.
BASF held sales close to flat, Dow swung to a GAAP Q1 loss on heavier costs, and DuPont raised full-year guidance after a 4 percent sales lift - three Q1 2026 prints that diverge sharply on margin trajectory.
Cross-read of Q1 2026 prints from six analytical-instrument vendors: bioprocessing and semiconductor metrology are funding capex, while academic and core industrial demand stays cautious.
Revvity reported Q1 2026 revenue of $711 million and signed a letter of intent to sell its China Immunodiagnostics business for up to $200 million, citing persistent policy headwinds.
Bruker reported $823.4 million in Q1 2026 revenue, up 2.7% on a 4.5% FX tailwind, but organic growth was negative 4.4% even as BSI bookings rose at a high-single-digit pace for a third straight quarter.
Agilent reported $1.80 billion in first-quarter fiscal 2026 revenue, up 7.0% reported and 4.4% on a core basis, with all three operating segments growing ahead of the May 27 second-quarter release.
Thermo Fisher's Analytical Instruments segment posted $1.72 billion in Q1 2026 revenue, flat year-on-year, with a 2% organic decline tied to softer academic and government demand.
BASF, Dow, and LyondellBasell all reported Q1 2026 results that point to tight capex, footprint rationalisation, and cost programmes - shifting process-analytics demand toward brownfield retrofits, not greenfield builds.